Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world patient characteristics, treatment patterns, and outcomes in patients with myelodysplastic syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

SZShiyun ZhuKPKenneth Poon

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis reveals treatment patterns and outcomes in lower-risk myelodysplastic syndrome patients, suggesting important implications for patient care.

Key Points

  • To describe characteristics and treatment patterns of patients with myelodysplastic syndromes (MDS) in a large health system.
  • Retrospective cohort analysis of adult patients with MDS diagnosed by bone marrow analysis at Kaiser Permanente Northern California.
  • Data collected through electronic medical record extraction and manual chart review.
  • Exclusion criteria included active non-MDS malignancies and history of kidney transplant.
  • 74.5% of patients had lower-risk MDS, with a median age of 75.4 years.
  • Median overall survival was 4.1 years for lower-risk MDS patients.
  • 30.6% of lower-risk MDS patients received erythropoietin-stimulating agents as first-line therapy.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4f6https://doi.org/10.1182/blood-2025-7398
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents2024 · 2 citations
  2. 2Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US2025 · 1 citations
  3. 3From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS2025
  4. 4Treatment patterns and overall survival among patients with myelodysplastic syndromes treated in the US community oncology setting: a real-world retrospective observational study2025
  5. 5Real-world treatment patterns and outcomes of patients with myelodysplastic syndrome by line of therapy2025